title: Propranolol reduces the rebleeding rate during endoscopic sclerotherapy before variceal obliteration.
abstract: In patients treated with sclerotherapy, most rebleeding episodes are observed before variceal obliteration. This prospective randomized study aimed to assess if propranolol together with sclerotherapy could reduce the rebleeding rate before variceal obliteration. Seventy-five patients (59 male, 16 female; mean age, 54 +/- 15 years) with cirrhosis (from alcohol abuse in 91%) admitted with upper gastrointestinal bleeding, which was endoscopically proven to originate from ruptured esophageal varices, were included. After initial control of bleeding, the patients were randomized into the following two groups: group 1 treated with sclerotherapy alone (36 patients) and group 2 treated with sclerotherapy plus propranolol (39 patients). They were followed up to variceal obliteration. In group 2, 7 patients rebled as compared with 14 patients treated with sclerotherapy alone (P less than 0.005). When considering only rebleedings from esophageal varices, 4 patients rebled in group 2 vs. 10 in group 1 (P less than 0.10). The total number of rebleeding episodes was lower in group 2 than in group 1 whether considering all causes (8 vs. 17; P less than 0.07) or variceal rebleedings alone (4 vs. 13; P less than 0.01). Mean total blood requirement per patient was lower in group 2 than in group 1 (1.4 +/- 3.4 vs. 2.79 +/- 6.4 units of blood, respectively; P less than 0.01). Mortality was similar in both groups of patients (14% vs. 13% in groups 1 and 2, respectively, NS). It is concluded that patients treated with sclerotherapy should be given propranolol before variceal obliteration.
authors.affiliation: Service d'hépato-gastro-entérologie, Centre Hospitalier, Universitaire Purpan, Toulouse, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Vinel
authors.forename: H
authors.initials: H
authors.lastname: Lamouliatte
authors.forename: P
authors.initials: P
authors.lastname: Cales
authors.forename: J M
authors.initials: JM
authors.lastname: Combis
authors.forename: D
authors.initials: D
authors.lastname: Roux
authors.forename: H
authors.initials: H
authors.lastname: Desmorat
authors.forename: B
authors.initials: B
authors.lastname: Pradere
authors.forename: G
authors.initials: G
authors.lastname: Barjonet
authors.forename: A
authors.initials: A
authors.lastname: Quinton
authors.forename: G
authors.initials: G
authors.lastname: Barjonnet
mesh_terms: D000328:Adult; D000368:Aged; D004932:Esophageal and Gastric Varices / Q000628:therapy*; D004945:Esophagoscopy; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use*; D012008:Recurrence; D015911:Sclerotherapy
chemical_list: D011433:Propranolol